Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
Director Steven B. Binder of Mannkind Corp (NASDAQ:MNKD) sold 75,367 shares of common stock on July 16, 2025, at a weighted average price of $3.94, for a total value of $296945. Prices ranged from $3.91 to $3.97. The sale was executed under a Rule 10b5-1 trading plan established on August 16, 2024. The transaction comes as Mannkind, currently valued at $1.19 billion, trades near its 52-week low of $3.51, having declined about 39% year-to-date. According to InvestingPro, the company maintains a "GREAT" financial health score, with liquid assets exceeding short-term obligations.
On July 15, Binder also disposed of 19,383 shares at $3.85, to cover tax obligations, for a total value of $74624.
Following these transactions, Binder directly owns 830,508 shares of Mannkind Corp.
In other recent news, MannKind Corporation reported its Q1 2025 financial results, revealing a mixed performance. The company’s revenue exceeded expectations, reaching $78.35 million, an 18% increase year-over-year, driven by strong Tyvaso DPI royalties and collaboration services. However, earnings per share (EPS) slightly missed forecasts, coming in at $0.04 compared to the anticipated $0.042. H.C. Wainwright assumed coverage of MannKind with a Buy rating, highlighting Tyvaso DPI as a significant value driver, while expressing caution over the Afrezza product line. Meanwhile, MannKind is set to present findings from its INHALE-1 clinical trial at the American Diabetes Association’s Scientific Sessions, focusing on the efficacy and safety of Afrezza for pediatric use. Additionally, the company announced the departure of its Chief Medical (TASE:BLWV) Officer, Burkhard Blank, who will step down from his executive role in August 2025. Despite the leadership change, MannKind remains focused on its strategic growth initiatives and pipeline advancements, including the potential approval of pediatric Afrezza.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.